市场调查报告书
商品编码
1500392
下一代 IVD 市场:按产品、应用和最终用户划分 - 2024-2030 年全球预测Next-Generation IVD Market by Product (Consumables, Instruments, Software), Application (Autoimmune Diseases, Cardiology, Diabetes), End-user - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
下一代IVD市场规模预计2023年为625.2亿美元,2024年达到656亿美元,预计2030年将达到893.9亿美元,复合年增长率为5.23%。
下一代体外诊断(IVD)是指在人类体外受控环境(例如试管或实验室)中进行的先进诊断测试。这些创新诊断涵盖各种技术、工具和方法,旨在更准确、快速、有效率地检测和监测疾病、病症和感染疾病。 「下一代」一词强调这些诊断结合了分子诊断、照护现场技术和数位健康技术的进步,比传统方法得到了显着增强。同时,感染疾病和慢性病的全球流行正在推动下一代体外诊断的发展。然而,下一代体外诊断药物的监管情况复杂且严格,核准往往需要时间。此外,保险报销政策并不总是有利于新的诊断技术,从而影响了市场渗透率。此外,次世代定序、聚合酵素链锁反应(PCR) 和生物晶片等技术创新显着提高了诊断测试的准确性、速度和可靠性,推动了对下一代 IVD 解决方案的需求。
主要市场统计 | |
---|---|
基准年[2023] | 625.2亿美元 |
预测年份 [2024] | 656亿美元 |
预测年份 [2030] | 893.9亿美元 |
复合年增长率(%) | 5.23% |
区域洞察
在美洲,美国和加拿大在研究和开发方面处于领先地位,这得益于对研究的大量投资和强大的专利框架。消费者对早期疾病检测和个人化治疗的好处的高度认识正在推动该地区对先进体外诊断 (IVD) 解决方案的需求。最近政府采取的旨在将下一代诊断纳入国家卫生计画的倡议进一步推动了对下一代体外诊断的需求。 EMEA(欧洲、中东和非洲)地区的特点是强劲成长和创新技术进步。该市场是由慢性病的增加以及基因组学和蛋白质组学在诊断中的整合所推动的。欧洲、中东和非洲地区的法规环境也不断调整,旨在促进创新,同时确保病患安全,在市场动态中发挥关键作用。此外,亚太地区向下一代体外诊断的转变主要是由医疗保健领域对快速、准确和个人化诊断解决方案不断增长的需求所推动的。该地区人口众多且老化,以及对疾病早期检测意识的增强是推动市场发展的关键因素。此外,旨在改善医疗基础设施和可近性的政府措施和研发投资正在促进先进 IVD 技术的整合。
FPNV定位矩阵
FPNV 定位矩阵对于评估供应商在下一代 IVD 市场的定位至关重要。此矩阵提供了对供应商的全面评估,并检验了与商务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果,供应商被分为代表其成功程度的四个像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可对下一代 IVD 市场中供应商的现状进行深入而详细的评估。对供应商贡献的彻底比较和分析可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他关键指标。此外,该分析还提供了对该行业竞争力的宝贵见解,包括研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息,供应商可以做出更明智的决策并製定有效的策略,以在市场竞争中保持领先地位。
策略分析与建议
策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对目前在下一代 IVD 市场中的地位进行全面评估,使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析,以确定核心优势和需要改进的领域。
[194 Pages Report] The Next-Generation IVD Market size was estimated at USD 62.52 billion in 2023 and expected to reach USD 65.60 billion in 2024, at a CAGR 5.23% to reach USD 89.39 billion by 2030.
Next-Generation In Vitro Diagnostics (IVD) refers to the advanced phase of diagnostics tests conducted outside a human body, in a controlled environment such as a test tube or a laboratory. These innovative diagnostics encompass various technologies, tools, and methods designed to offer more precise, faster, and more efficient detection and monitoring of diseases, conditions, and infections. The term 'Next-Generation' underscores the significant enhancements these diagnostics represent over traditional methods, incorporating advancements in molecular diagnostics, point-of-care techniques, and digital health technologies. Meanwhile, the growing prevalence of infectious and chronic diseases worldwide is propelling the growth of next-generation IVDs. However, the regulatory landscape for next-generation IVDs can be complex and rigorous, often resulting in longer approval times. Additionally, reimbursement policies may not always favor novel diagnostic technologies, impacting their market penetration. Moreover, continuous innovation in technologies such as next-generation sequencing, polymerase chain reaction (PCR), and biochips are significantly enhancing diagnostic tests' accuracy, speed, and reliability, thus driving the demand for next-generation IVD solutions.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 62.52 billion |
Estimated Year [2024] | USD 65.60 billion |
Forecast Year [2030] | USD 89.39 billion |
CAGR (%) | 5.23% |
Regional Insights
In the Americas, the United States and Canada are at the forefront of next-generation IVD development, spurred by significant investments in research and a strong patent framework. High consumer awareness about the benefits of early disease detection and personalized treatment plans drives the region's demand for advanced IVD solutions. Recent government initiatives focused on incorporating next-generation diagnostics in national health programs further drive the demand for next-generation IVDs. The EMEA region has been characterized by robust growth and transformative technological advancements. The market is driven by the increasing prevalence of chronic diseases and the integration of genomics and proteomics in diagnostics. Regulatory environments across EMEA have also adapted, aiming to foster innovation while ensuring patient safety, thereby playing a pivotal role in market dynamics. Moreover, the shift towards next-generation IVDs in the Asia-Pacific region is primarily fueled by the increasing demand for fast, accurate, and personalized diagnostic solutions across the healthcare sector. The region's large and aging population and the growing awareness about early disease detection are key factors propelling the market forward. Furthermore, government initiatives aimed at improving healthcare infrastructure and accessibility, coupled with investments in research and development, are facilitating the integration of advanced IVD technologies.
Market Insights
The market dynamics represent an ever-changing landscape of the Next-Generation IVD Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Next-Generation IVD Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Next-Generation IVD Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Strategic Collaboration: Illumina and Devyser Diagnostics Forge Path in IVD Innovation
Illumina, the pioneer in DNA sequencing and array-based technologies, has entered a strategic agreement with Devyser Diagnostics. By leveraging Illumina's formidable expertise in genomics alongside Devyser Diagnostics' specialized focus on diagnostic testing solutions, this collaboration marks a critical step forward in developing novel IVD offerings. [Published On: 2024-01-08]
Fapon Biotech Advances IVD Landscape and Targets Next-Generation Therapeutics Expansion
Fapon Biotech is strategically expanding its comprehensive solutions, encompassing IVD raw materials and end-use product development services. This initiative is characterized by their significant investments in next-generation therapeutics, specifically in infectious diseases and oncology. [Published On: 2023-09-15]
Waters Corporation Introduces Revolutionary Xevo TQ Absolute IVD Mass Spectrometer
Waters Corporation unveiled the Xevo TQ Absolute IVD Mass Spectrometer, poised to redefine efficiency and sensitivity in clinical diagnostics. This cutting-edge instrument departs from traditional mass spectrometry techniques by offering unparalleled analytical performance and ease of use. The Xevo TQ Absolute IVD stands out for its remarkably compact design, which requires 50% less bench space, alongside an enhanced sensitivity that promises to accelerate lab workflows by doubling the number of tests conducted within the same timeframe. [Published On: 2023-04-04]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Next-Generation IVD Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Next-Generation IVD Market, highlighting leading vendors and their innovative profiles. These include ABL SA Group, Agilent Technologies Inc., Archer by Integrated DNA Technologies, Inc., Becton, Dickinson and Company, Biomerieux SA, BioVendor - Laboratorni medicina A.S., Cerba Research NV, Curetis N.V., Danaher Corporation, F. Hoffmann-La Roche Ltd., Fapon Biotech Inc., Fulgent Genetics, Inc., Geneseeq Technology Inc., Genomic Labs Ltd., Illumina, Inc., Invivoscribe, Inc., NGenBio Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Pillar Biosciences Inc., QIAGEN GmbH, Sophia Genetics SA, Sysmex Europe SE, Tempus Labs, Inc., Thermo Fisher Scientific Inc., Trivitron Healthcare, and Vela Diagnostics Holding Pte Ltd..
Market Segmentation & Coverage